Notably, cIAP2 (a mediator and an indicator of NF-κB activity) is upregulated in glioblastoma tumours, showing that cIAP2 promotes tumorigenesis and further drives therapeutic resistance18, 19, 20. Here, NFKB1 is linked to glioblastoma.